Assenagon Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Assenagon Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.4M	Buy	+280,649	New	+$24.5M	0.03%	348

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Assenagon Asset Management's DNTH Position: Q2 2026 in Review

Assenagon Asset Management opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 280,649 shares worth $27.4M. The stake represents 0.03% of the portfolio and ranks #348 among its holdings.

268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Assenagon Asset Management held 280,649 shares of Dianthus Therapeutics worth $27.4M as of Q2 2026.
Dianthus Therapeutics was a new Assenagon Asset Management position in Q2 2026.
Dianthus Therapeutics made up 0.03% of Assenagon Asset Management's portfolio in Q2 2026, its #348 holding.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.